United States Hydroxyapatite market is expected to reach 78.61 million USD by the end of 2024

Publisher: QYResearch

Published Date: 2018/11/29

Hydroxyapatite is chemically similar to the mineral component of bones and hard tissues in mammals. It widely used in Orthopaedic, Dental etc.

The United States Hydroxyapatite market is valued at 43.38 million USD in 2017 and is expected to reach 78.61 million USD by the end of 2024, growing at a CAGR of 8.97% between 2018 and 2024.

At present, the major manufacturers of Hydroxyapatite are concentrated in SofSera, Fluidinova, Bio-Rad, Bonesupport AB, Sigma Graft, Berkeley Advanced Biomaterials, etc. SofSera is the world leader.

Hydroxyapatite is the most widely accepted biomaterial for the repair and reconstruction of bone tissue defects. It has all the characteristic features of biomaterials. So hydroxyapatite downstream is wide and recently Hydroxyapatite has acquired increasing significance in various fields of Orthopaedic, Dental, Biochemical Research and others.

In the future, United States market is expected to witness significant growth on account of rising applications, so in the next few years, Hydroxyapatite production will show a trend of steady growth. In 2024 the production of Hydroxyapatite is estimated to be 17988 Kg. On product prices, the slow upward trend in recent years will maintain in the future.

Click to view the full report: https://www.qyresearch.com/index/detail/327325/united-states-hydroxyapatite-market

This article was first released by QYResearch, if reproduced, please indicate the source.

Marketing: sales@qyresearchglobal.com

Media Contact: press@qyresearch.com